Applied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman Acquires 701 Shares of Stock

Applied Therapeutics, Inc. (NASDAQ:APLT) CEO Shoshana Shendelman purchased 701 shares of the firm’s stock in a transaction on Monday, September 13th. The shares were acquired at an average cost of $14.69 per share, for a total transaction of $10,297.69. Following the completion of the purchase, the chief executive officer now directly owns 354,986 shares of the company’s stock, valued at approximately $5,214,744.34. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NASDAQ APLT opened at $14.20 on Wednesday. Applied Therapeutics, Inc. has a 52 week low of $13.58 and a 52 week high of $29.80. The firm’s fifty day moving average is $17.45 and its 200 day moving average is $18.55. The company has a market cap of $371.73 million, a price-to-earnings ratio of -3.24 and a beta of 1.13.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Wednesday, August 11th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.14. As a group, equities analysts predict that Applied Therapeutics, Inc. will post -4.2 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC boosted its holdings in Applied Therapeutics by 27.4% in the first quarter. Orbimed Advisors LLC now owns 2,257,387 shares of the company’s stock valued at $42,337,000 after acquiring an additional 485,556 shares in the last quarter. BlackRock Inc. boosted its holdings in Applied Therapeutics by 9.0% in the second quarter. BlackRock Inc. now owns 1,312,102 shares of the company’s stock valued at $27,266,000 after acquiring an additional 108,372 shares in the last quarter. Knoll Capital Management LLC boosted its holdings in Applied Therapeutics by 0.6% in the second quarter. Knoll Capital Management LLC now owns 1,032,123 shares of the company’s stock valued at $21,448,000 after acquiring an additional 6,659 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Applied Therapeutics by 1.3% in the second quarter. Vanguard Group Inc. now owns 844,882 shares of the company’s stock valued at $17,557,000 after acquiring an additional 10,713 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Applied Therapeutics by 10.8% in the second quarter. Franklin Resources Inc. now owns 829,982 shares of the company’s stock valued at $17,247,000 after acquiring an additional 81,000 shares in the last quarter. Institutional investors and hedge funds own 58.72% of the company’s stock.

Several research firms have commented on APLT. Zacks Investment Research downgraded shares of Applied Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday. Robert W. Baird reissued a “buy” rating and set a $35.00 price target on shares of Applied Therapeutics in a research note on Sunday. Finally, The Goldman Sachs Group downgraded shares of Applied Therapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $16.00 to $10.00 in a research note on Thursday, August 26th.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc operates as a clinical-stage biopharmaceutical company. The firm engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Featured Article: Why are analyst ratings important in trading stocks?

Insider Buying and Selling by Quarter for Applied Therapeutics (NASDAQ:APLT)

Receive News & Ratings for Applied Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.